Literature DB >> 12523819

GEX1 compounds, novel antitumor antibiotics related to herboxidiene, produced by Streptomyces sp. II. The effects on cell cycle progression and gene expression.

Yasushi Sakai1, Tetsuya Tsujita, Tadakazu Akiyama, Tatsuhiko Yoshida, Tamio Mizukami, Shiro Akinaga, Sueharu Horinouchi, Minoru Yoshida, Tetsuo Yoshida.   

Abstract

Six GEX1 compounds, GEX1A/herboxidiene and its related 5 novel compounds, were isolated from a culture broth of Streptomyces sp. GEX1 compounds induced both G1 and G2/M arrest in a human normal fibroblast cell line, WI-38. All six compounds up-regulated luciferase reporter gene expression directed by enhancer/promoter of various genes, such as cdc2, IL-2 and SV40 early genes. All GEX1 compounds showed cytotoxic activities in the same order of the up-regulating activities on gene expression, suggesting that these two activities are related. Despite the up-regulating activities on the reporter gene expression, GEX1A/herboxidiene did not enhance the expression of any endogenous genes involved in the cell cycle, proliferation and apoptosis. Although the unique effects of GEX1 compounds on cell cycle and the reporter gene expression were similar to those of trichostatin A (TSA), an inhibitor of histone deacetylase (HDAC), GEX1A/herboxidiene did not affect histone acetylation in cells. In addition, GEX1A/herboxidiene treatment gave rise to the shorter sized transcripts of the cdc25A and cdc2 genes as well as the normal sized ones. These results suggest that GEX1 compounds modulate gene expression by an unknown mechanism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12523819     DOI: 10.7164/antibiotics.55.863

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  29 in total

1.  Total synthesis of herboxidiene/GEX 1A.

Authors:  Yun Zhang; James S Panek
Journal:  Org Lett       Date:  2007-07-13       Impact factor: 6.005

2.  Total syntheses, fragmentation studies, and antitumor/antiproliferative activities of FR901464 and its low picomolar analogue.

Authors:  Brian J Albert; Ananthapadmanabhan Sivaramakrishnan; Tadaatsu Naka; Nancy L Czaicki; Kazunori Koide
Journal:  J Am Chem Soc       Date:  2007-02-06       Impact factor: 15.419

3.  Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464.

Authors:  Sami Osman; Brian J Albert; Yanping Wang; Miaosheng Li; Nancy L Czaicki; Kazunori Koide
Journal:  Chemistry       Date:  2010-11-19       Impact factor: 5.236

4.  Identification of the herboxidiene biosynthetic gene cluster in Streptomyces chromofuscus ATCC 49982.

Authors:  Lei Shao; Jiachen Zi; Jia Zeng; Jixun Zhan
Journal:  Appl Environ Microbiol       Date:  2012-01-13       Impact factor: 4.792

5.  Achmatowicz Reaction and its Application in the Syntheses of Bioactive Molecules.

Authors:  Arun K Ghosh; Margherita Brindisi
Journal:  RSC Adv       Date:  2016-11-24       Impact factor: 3.361

6.  A stereoselective synthesis of (+)-herboxidiene/GEX1A.

Authors:  Arun K Ghosh; Jianfeng Li
Journal:  Org Lett       Date:  2010-12-02       Impact factor: 6.005

7.  Optimization of antitumor modulators of pre-mRNA splicing.

Authors:  Chandraiah Lagisetti; Gustavo Palacios; Tinopiwa Goronga; Burgess Freeman; William Caufield; Thomas R Webb
Journal:  J Med Chem       Date:  2013-12-11       Impact factor: 7.446

Review 8.  Modulating splicing with small molecular inhibitors of the spliceosome.

Authors:  Kerstin A Effenberger; Veronica K Urabe; Melissa S Jurica
Journal:  Wiley Interdiscip Rev RNA       Date:  2016-07-21       Impact factor: 9.957

9.  Design, synthesis and in vitro splicing inhibition of desmethyl and carba-derivatives of herboxidiene.

Authors:  Arun K Ghosh; Kai Lv; Nianchun Ma; Emilio L Cárdenas; Kerstin A Effenberger; Melissa S Jurica
Journal:  Org Biomol Chem       Date:  2016-05-18       Impact factor: 3.876

Review 10.  The spliceosome as a target of novel antitumour drugs.

Authors:  Sophie Bonnal; Luisa Vigevani; Juan Valcárcel
Journal:  Nat Rev Drug Discov       Date:  2012-11       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.